feb 12, 2018: 4 p.m. - 4:55 p.m.
2017 produced seven FDA approvals for new dermatology medicines, the most since 2014. Additionally, several treatments in late-stage clinical development suggest opportunities for new help for patients suffering from some chronic and acute skin ailments. This session will examine some of the exciting clinical results illuminating biological understanding of dermatological diseases and the emerging opportunities for investors in this space.
Moderator: Umer Raffat, Senior Managing Director, Evercore ISI
Michael Derby, Founder and Chief Executive Officer, Castle Creek Pharmaceuticals, LLC
Luis Peña, Founder & Chief Development Officer, Dermira, Inc.
Michael Sierra, PhD, Vice President, LEO Science & Tech Hub